344
“Semaglutide is not part of the WHO recommended treatments for diabetes because of its current high cost. The price barrier makes these products unsuitable for public health.”
Advertising
The World Health Organization (WHO) this Thursday issued a warning about counterfeit semaglutide, a medication used to treat type 2 diabetes and weight loss.
According to WHO, the warning concerns three counterfeit batches of products from the semaglutide class (specific brand name Ozempic ) that were detected in Brazil in October 2023, in the United Kingdom and Northern Ireland in October 2023, and in the United States in December 2023.
